Archiv | Archiv 2022 | Year in Review 2022
Mammakarzinom HR+ Year in Review


ADAPT; Cycle monarchE
Year in Review 2022
EBC - Endokrine Response / CDK4/6i Benefit / PARPi…


MONARCH 3; PALOMA-2; RIGHT Choice; EMERALD; AMEERA; acelERA BC; TROPICS-02; DESTINY-Breast04
Year in Review
MBC Unterschiede: CDK4/6i & SERDs; Update: ADC &…


Alliance; OMA; POLAR
Year in Review 2022
Hypofraktionierung / RT LAW / SLNE oder TAD
Mammakarzinom HER2+ Year in Review


APHINITY; KAITLIN; PerELISA; ADAPT; IMpassion050
Year in Review 2022
EBC Adjuvant / Neoadjuvant / Immuntherapie


DESTINY-Breast02; DESTINY-Breast03; DETECT V; HER2CLIMB; TUXEDO-1
Year in Review 2022
MBC ADC / Triplepositives MBC / Hirnmetastasen


Alliance; OMA; POLAR
Year in Review 2022
Hypofraktionierung / RT LAW / SLNE oder TAD
Mammakarzinom TNBC Year in Review


DESTINY-Breast04; KEYNOTE-355
Year in Review 2022
MBC – Immuntherapie, CPS / ADC


KEYNOTE-522; NeoMono; NACT; OlympiA
Year in Review 2022
EBC – Immuntherapie /Carboplatin?/PARPi


Alliance; OMA; POLAR
Year in Review 2022
Hypofraktionierung / RT LAW / SLNE oder TAD
GI Tumoren Year in Review


Year in Review 2022
Year in Review: Upper GI


Year in Review 2022
Year in Review: HCC und BTC


Year in Review 2022
Year in Review: Pankreas-Ca


Year in Review 2022
Year in Review: CRC
Präzisionsonkologie Year in Review


Year in Review 2022
Year in Review: Präzisionsonkologie